Andrew Guggenhime Vaxcyte, Inc. (PCVX) insider trading activity

Andrew Guggenhime is PRESIDENT AND CFO of Vaxcyte, Inc.. Currently has a direct ownership of 109,491 shares of PCVX, which is worth approximately $9.41 Million. The most recent transaction as insider was on Jan 18, 2024, when has been sold 8,000 shares (Common Stock) at a price of $5.35 per share, resulting in proceeds of $42,800. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 109K

13.2% 3M change

37.77% 12M change

Total Value Held $9.41 Million

ANDREW GUGGENHIME Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 8.38%	87,474 Common Stock
Dec 18 2023	SELL Open market or private sale	$483,840 $60.48 p/Share	8,000 Reduced 9.15%	79,474 Common Stock
Dec 18 2023	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 8.38%	87,474 Common Stock
Dec 14 2023	SELL Open market or private sale	$843,080 $60.22 p/Share	14,000 Reduced 14.98%	79,474 Common Stock
Dec 14 2023	BUY Exercise of conversion of derivative security	$74,900 $5.35 p/Share	14,000 Added 13.03%	93,474 Common Stock
Nov 20 2023	SELL Open market or private sale	$412,320 $51.54 p/Share	8,000 Reduced 9.15%	79,474 Common Stock
Nov 20 2023	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 8.38%	87,474 Common Stock
Oct 18 2023	SELL Open market or private sale	$368,800 $46.1 p/Share	8,000 Reduced 9.15%	79,474 Common Stock
Oct 18 2023	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 8.38%	87,474 Common Stock
Sep 05 2023	SELL Payment of exercise price or tax liability	$181,968 $51.0 p/Share	3,568 Reduced 4.3%	79,474 Common Stock
Mar 02 2023	SELL Payment of exercise price or tax liability	$71,653 $41.49 p/Share	1,727 Reduced 2.06%	82,002 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	22,500 Added 21.18%	83,729 Common Stock
Dec 30 2022	BUY Exercise of conversion of derivative security	$126,746 $5.35 p/Share	23,691 Added 27.9%	61,229 Common Stock
Sep 19 2022	SELL Open market or private sale	$81,437 $26.27 p/Share	3,100 Reduced 7.63%	37,538 Common Stock
Sep 19 2022	BUY Exercise of conversion of derivative security	$16,585 $5.35 p/Share	3,100 Added 7.09%	40,638 Common Stock
Sep 02 2022	SELL Payment of exercise price or tax liability	$122,641 $26.38 p/Share	4,649 Reduced 11.02%	37,538 Common Stock
Aug 29 2022	SELL Open market or private sale	$494,284 $28.0 p/Share	17,653 Reduced 29.5%	42,187 Common Stock
Aug 29 2022	BUY Exercise of conversion of derivative security	$94,444 $5.35 p/Share	17,653 Added 22.78%	59,840 Common Stock
Aug 26 2022	SELL Open market or private sale	$36,260 $28.0 p/Share	1,295 Reduced 2.98%	42,187 Common Stock
Aug 26 2022	BUY Exercise of conversion of derivative security	$6,928 $5.35 p/Share	1,295 Added 2.89%	43,482 Common Stock
Aug 25 2022	SELL Open market or private sale	$477,456 $28.0 p/Share	17,052 Reduced 28.79%	42,187 Common Stock
Aug 25 2022	BUY Exercise of conversion of derivative security	$91,228 $5.35 p/Share	17,052 Added 22.35%	59,239 Common Stock
Aug 18 2022	SELL Open market or private sale	$79,081 $25.51 p/Share	3,100 Reduced 6.85%	42,187 Common Stock
Aug 18 2022	BUY Exercise of conversion of derivative security	$16,585 $5.35 p/Share	3,100 Added 6.41%	45,287 Common Stock
Jul 18 2022	SELL Open market or private sale	$76,787 $24.77 p/Share	3,100 Reduced 6.85%	42,187 Common Stock

Also insider at

MTCR

Metacrine, Inc. Healthcare

Director

CRBU

Caribou Biosciences, Inc. Healthcare

Director